Trice Medical

Trice Medical develops imaging and surgical solutions to simplify routine procedures, reduce procedure time, and enable quicker patient recovery. The company's flagship product is the Dynamic Imaging Platform, which combines two technologies: The mi-eye 2, which is a handheld, single-use, disposable arthroscopy camera that provides physicians with clear visualization of the interior of joints and cavities, and the mi-ultra, a compact and portable ultrasound device. The mi-eye 3 needlescope is ideal for patients who cannot undergo an MRI due to conditions such as claustrophobia, pacemakers, metal implants, obesity, or anxiety.

The mi-eye 2 is a disposable needle camera that provides high-quality, real-time imaging during orthopedic procedures. The Dynamic Imaging Platform offers a comprehensive in-office diagnostics solution when paired with the mi-ultra ultrasound transducer. This allows physicians to visualize and diagnose joint injuries with unparalleled clarity, expediency, and convenience. In addition, it enables complex procedures to be performed in outpatient settings, such as procedure rooms or physician offices, without the need for expensive infrastructure and staffing associated with operating rooms.

In February 2019, the company acquired SegWAY Orthopaedics, gaining access to solutions like the Endoscopic Carpal Tunnel Release system. Further in April 2021, Trice Medical acquired Tenex Health to expand Trice's portfolio to include the Tenex TX system for the percutaneous removal of calcifications, osteophytes, and spur formations, as well as an effective treatment option for diabetic foot ulcers.

Key customers and partnerships

Trice Medical provides imaging and surgical solutions to the healthcare sector, primarily targeting orthopedic and outpatient settings.

In October 2022, Trice Medical partnered with Clarius Mobile Health to develop the world’s first platform, which enables orthopedic physicians to use high-definition wireless ultrasound and a single-use handheld arthroscope on a single tablet. In August 2021, Bioventus invested strategically in Trice Medical and obtained distribution rights for Trice’s products outside of the US.